DESCRIPTIVE EPIDEMIOLOGY AND TREATMENT STRATEGIES USED IN MULTIPLY MYELOMA IN THE SLOVAK REPUBLIC. RESULTS FROM THE CROSS-SECTIONAL SURVEY IN THE HAEMATOLOGY-ONCOLOGICAL CENTERS
Author(s)
Ondrusova M1, Psenkova M1, Suchansky M1, Chudej J2
1Pharm-In Ltd, Bratislava, Slovak Republic, 2University hospital Martin, Martin, Slovak Republic
OBJECTIVES: The latest official national data on epidemiology of multiply myeloma (MM) are available for year 2008. Estimated incidence for 2015 represents in both sexes 311 cases (age-standardized (ASR-W) incidence 3.1/100,000), mortality 176 cases (ASR-W 1.6/100,000), prevalence 1,715 patients. The objective of this cross-sectional survey was to define prevalence and treatment strategies used in MM patients according to the treatment lines and provide a basis for the budget impact analysis (BIA). METHODS: Data on treatment of 656 MM patients from 7 MM-centers in 2013 from whole Slovakia were collected and analyzed. Continuous variables were calculated using standard descriptive statistics methods RESULTS: st clinical stage (according to Durie and Salmon classification) were 13.03% of patients, in the 2nd clinical stage-32.07%, in the 3rd clinical stage-54.09%. The treatment strategies were as followed: In the 1st line-36.34% of patients underwent BMT, outside them 80.53% were on bortezomib regimen, mean-time to progression represented 2.31 years. In the 2nd line-22.83% (out of 36.34%) of patients underwent re-transplant, outside them 68.50% were on lenalidomid regimen, mean-time to progression was 1.65 years. In the 3rd line-42.84%/21.71%/12.97% of patients were on bortezomib/lenalidomid/bendamustine regimens, mean-time to progression represented 1.29 year. 40.88% of all registered patients were in 2013 treated by the 4th line, 90.45% out of them had previously been treated by bortezomib and/or lenalidomid regimen and cross-sectionally 45.07%/24.73%/8.51% were treated by lenalidomid/bortezomib/conventional chemotherapy regimens, mean time to progression was 0.81 year. In the 5th line-34.19%/18.36%/18.36% of patients were treated by lenalidomid/bortezomib/conventional chemotherapy regimens, mean-time to progression was 0.88 years. In the 6th line-60.20% of patients were treated by conventional chemotherapy. CONCLUSIONS: This cross-sectional survey determined the prevalence and treatment strategies of MM patients in Slovakia according to the treatment lines.
Conference/Value in Health Info
2015-11, ISPOR Europe 2015, Milan, Italy
Value in Health, Vol. 18, No. 7 (November 2015)
Code
PCN204
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Oncology